236 related articles for article (PubMed ID: 24445562)
1. Biosimilar competition: lessons from Europe.
Grabowski H; Guha R; Salgado M
Nat Rev Drug Discov; 2014 Feb; 13(2):99-100. PubMed ID: 24445562
[No Abstract] [Full Text] [Related]
2. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
3. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
4. [Biosimilar medicines. Scientific and legal disputes].
Dorantes Calderón B; Montes Escalante IM
Farm Hosp; 2010 Mar; 34 Suppl 1():29-44. PubMed ID: 20920856
[TBL] [Abstract][Full Text] [Related]
5. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
Simoens S; Huys I
Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
[TBL] [Abstract][Full Text] [Related]
6. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
7. Friction in the Path to Use of Biosimilar Drugs.
Frank RG
N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182
[No Abstract] [Full Text] [Related]
8. The comparability conundrum: biosimilars in the United States, Europe and Canada.
Courage N; Parsons A
Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
[TBL] [Abstract][Full Text] [Related]
9. Competition in the Age of Biosimilars.
Chandra A; Vanderpuye-Orgle J
JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179
[No Abstract] [Full Text] [Related]
10. Biosimilars.
Ross A; Richard K
Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019
[No Abstract] [Full Text] [Related]
11. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
12. [Introduction of biosimilars requires careful monitoring].
Marsal J; Hertervig E
Lakartidningen; 2016 Mar; 113():. PubMed ID: 26954925
[No Abstract] [Full Text] [Related]
13. Biosimilars and the European experience: implications for the United States.
Megerlin F; Lopert R; Taymor K; Trouvin JH
Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
[TBL] [Abstract][Full Text] [Related]
14. Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars battle rages on, Amgen fights both sides.
Senior M
Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
[No Abstract] [Full Text] [Related]
16. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
17. Bullying biosimilars: cheaper drugs stymied in USA.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
[No Abstract] [Full Text] [Related]
18. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
Reinke T
Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
[TBL] [Abstract][Full Text] [Related]
19. [Organization of the Federal Drug and Medical Products Institute in view of increased European competition].
Kurth R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Mar; 51(3):340-4. PubMed ID: 18369569
[No Abstract] [Full Text] [Related]
20. Biosimilars: where we were and where we are.
Challand R; Gorham H; Constant J
J Biopharm Stat; 2014; 24(6):1154-64. PubMed ID: 25036475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
